Viridian Therapeutics, Inc.
VRDN
$16.86
-$0.34-1.98%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 6.82% | -99.81% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 6.82% | -99.81% | |||
| Cost of Revenue | -22.56% | 7.47% | |||
| Gross Profit | 22.60% | -489.99% | |||
| SG&A Expenses | 14.87% | 38.45% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.97% | 14.29% | |||
| Operating Income | 7.98% | -215.52% | |||
| Income Before Tax | 12.84% | -247.86% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 12.84% | -247.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 12.84% | -247.86% | |||
| EBIT | 7.98% | -215.52% | |||
| EBITDA | 7.99% | -216.09% | |||
| EPS Basic | 15.92% | -210.95% | |||
| Normalized Basic EPS | 21.80% | -210.21% | |||
| EPS Diluted | 15.92% | -210.95% | |||
| Normalized Diluted EPS | 21.80% | -210.21% | |||
| Average Basic Shares Outstanding | 8.30% | 15.40% | |||
| Average Diluted Shares Outstanding | 8.30% | 15.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||